Well, Yahoo still shows that institutions hold 110% of the float so it may be true that to cover 10's of millions of shorted shares the shorts are going to need some hedge funds to bail. If they're highly leveraged they may be forced to.
"I visualize the reality I want and it appears!!"
I could swear I heard Cathleen Sebelius utter those words in a congressional hearing.
It was just announced that the back end payment system is so "incomplete" ( i.e. they havent started coding it yet) that for the forseeable future they're just going to throw whatever money the Ins. Co's "think" they are owed at them since they have no way of getting accurately paid without the backend payment system being in place to calculate the appropriate individual subsidies. Mr Rodgers, can you say CLUSTERF__K. ?
I wonder if the processes they put in place to scrub every post of stuff they dont like (which seems to grow exponentially) is taking so much bandwidth that it cannot keep up with all the postings during busy hours.
what IDIOT just game me a thumbs down?? If you don't believe me
go to the citron site and read it for yourself!! Idiot.
Wow, 2 million in 2 weeks. Seems excessive given that this latest Citron piece is much flimsier than the original Citron attacks. As someone else posted there is no official investigation and if if the FTC did an official investigation it would have to go to the courts to kill the deal which would take years. This level of shorting seems excessive.
Unfortunately this stock is controlled by the big players, not us retailers. The part that is unnerving is that the short, if he wants to, can literally drive this stock down to where it takes someone wanting to buy hundreds of thousands of shares in a single traunch to stop it from going down. Its a battle of the titans and none of the titans on the long side show us their hand to make us "feel" better.
Taken from the PR (Notice that there are required milestones and milestone payments to Novartis)
"This transaction leverages our rapidly growing understanding of the different characteristics and biological activity of melanocortin receptor agonists such as Synacthen, a synthetic ACTH-related agonist, and naturally derived Acthar, as well as the potential use of melanocortin receptor agonists in the treatment of serious and difficult-to-treat autoimmune and inflammatory disorders," said David Young, Pharm.D., Ph.D, Chief Scientific Officer of Questcor. "We intend to develop and seek FDA approval for Synacthen and are committed to developing this product not only in conditions different than Acthar but also in conditions where Synacthen would potentially provide a clinical benefit over Acthar."
Under the terms of the transaction agreements, Questcor has paid Novartis an upfront consideration of $60.0 million. Questcor will make additional payments of at least $75.0 million in the aggregate over the next several years, as well as potential milestone payments prior to FDA approval. Upon FDA approval of Synacthen in the U.S., Questcor will pay Novartis another milestone and royalties based on net sales in the U.S. As is common in the acquisition of development programs, the transaction agreements include mechanisms to ensure that Questcor pursues FDA approval and commercializes Synacthen in the U.S. upon approval. "
Is it not true that Novartis and Qcor mgmt have development milestones in place that prevent accusations of "pay for delay" from sticking??
If the investigation finds nothing wrong is the govt even obligated to notify the company of that? I thought in that case they just never take any punitive action and the absence of that action does not give any definitive closure to the matter. Perhaps I am misremembering how these things work out.
And this thread you started is part of it. Another wasted thread sprouts up. Congratulations. BTW, that was my thumbs down.